Meeting
2021 ASCO Annual Meeting
Impact of the COVID-19 pandemic on care delivery and outcomes for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Authors
Ravi Kumar Paluri
Wake Forest Baptist Health, Winston-Salem, NC
Ravi Kumar Paluri , Paul Cockrum , Ashley Ann Laursen , Joseph Louis Gaeta , Shu Wang , Andy Surinach
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4137)
DOI
10.1200/JCO.2021.39.15_suppl.4137
Abstract #
4137
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC; SGNS40-001).
First Author: Andrew L. Coveler
Poster
2022 ASCO Annual Meeting
Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Vincent J. Picozzi
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A multi-institutional study of the impact of the COVID-19 pandemic on pancreatic cancer diagnosis and management.
First Author: Claudia Rosso
Poster
2021 Gastrointestinal Cancers Symposium
Real-world outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma.
First Author: Laura Miotke